Article

Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension A Pilot Study

Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany.
Circulation (Impact Factor: 14.95). 05/2011; 123(18):1940-6. DOI: 10.1161/CIRCULATIONAHA.110.991869
Source: PubMed

ABSTRACT Hypertension is associated with impaired glucose metabolism and insulin resistance. Chronic activation of the sympathetic nervous system may contribute to either condition. We investigated the effect of catheter-based renal sympathetic denervation on glucose metabolism and blood pressure control in patients with resistant hypertension.
We enrolled 50 patients with therapy-resistant hypertension. Thirty-seven patients underwent bilateral catheter-based renal denervation, and 13 patients were assigned to a control group. Systolic and diastolic blood pressures, fasting glucose, insulin, C peptide, hemoglobin A(1c), calculated insulin sensitivity (homeostasis model assessment-insulin resistance), and glucose levels during oral glucose tolerance test were measured before and 1 and 3 months after treatment. Mean office blood pressure at baseline was 178/96±3/2 mm Hg. At 1 and 3 months, office blood pressure was reduced by -28/-10 mm Hg (P<0.001) and -32/-12 mm Hg (P<0.001), respectively, in the treatment group, without changes in concurrent antihypertensive treatment. Three months after renal denervation, fasting glucose was reduced from 118±3.4 to 108±3.8 mg/dL (P=0.039). Insulin levels were decreased from 20.8±3.0 to 9.3±2.5 μIU/mL (P=0.006) and C-peptide levels from 5.3±0.6 to 3.0±0.9 ng/mL (P=0.002). After 3 months, homeostasis model assessment-insulin resistance decreased from 6.0±0.9 to 2.4±0.8 (P=0.001). Additionally, mean 2-hour glucose levels during oral glucose tolerance test were reduced significantly by 27 mg/dL (P=0.012). There were no significant changes in blood pressure or metabolic markers in the control group.
Renal denervation improves glucose metabolism and insulin sensitivity in addition to a significantly reducing blood pressure. However, this improvement appeared to be unrelated to changes in drug treatment. This novel procedure may therefore provide protection in patients with resistant hypertension and metabolic disorders at high cardiovascular risk.
URL: http://www.ClinicalTrials.gov. Unique identifiers: NCT00664638 and NCT00888433.

Download full-text

Full-text

Available from: Lars Christian Rump, Jul 27, 2015
0 Followers
 · 
141 Views
  • Source
    • "Radiofrequency energy is being used due to the property of superficial and deep tissue destruction. Currently, nonirrigated [4] [5] [7] or irrigated [9] [10] catheters have been used, safely and effectively. In contrast to the use of fixed-curve sheath in a previous study from our group [9], we observed that the long steerable sheath demonstrated utmost facility at anchoring its tip at the ostia of renal arteries, allowing greater flexibility in positioning the ablation catheter. "
    International journal of cardiology 04/2014; 174(2). DOI:10.1016/j.ijcard.2014.04.048 · 6.18 Impact Factor
  • Source
    • " in pressure natriuresis toward higher pressures implies RAAS - resistance . The change in " set - function " appears to be centrally controlled , since renal sympathectomy is almost universally effective for uncontrolled hypertension ( Egan , 2011 ) . Unexpectedly , renal sympathectomy also ameliorates insulin resistance and glucose intolerance ( Mahfoud et al . , 2011 ) ."
    [Show abstract] [Hide abstract]
    ABSTRACT: The dorsovagal complex comprises: (1) a chemosensory structure, the area postrema (AP), (2) a center for integrating distension, mechanosensory and other inputs from the viscera, the nucleus of the tractus solitarius (NTS), and (3) a center to integrate motor and secretory drive to the viscera, the dorsal motor nucleus of the vagus (DMX). There is recent evidence for considerable autonomy of dorsovagal reflexes traversing this loop in ingestive control, especially in meal-termination/anorexic responses, and in other controls on nutrient flux. The characteristics of this system, including (1) activation of several parallel effector pathways, and (2) glucose-sensitivity (hypoglycemic override) have profound therapeutic implications for anti-diabetic and anti-obesity drug development. Agents acting via the brain structures similar to those activated by amylin promise efficacy via multiple effectors, but, via glucose-dependence of effects, without increased risk of hypoglycemia. Several peptides, including those secreted in response to meals, are sensed at area postrema, and because they degrade to innocuous metabolites (amino acids) are thereby candidates as safe and effective drugs. Recently developed GLP-1 agonists and amylin agonists are examples of the therapeutic potential of such agents for metabolic diseases. Others in development include PYY agonists and MC4 agonists. Especially promising may be combinations of peptides and/or their analogs. Certain pairs of peptides, including those acting via the dorsovagal complex, exhibit surprising synergies (eg amylin + CCK (Bhavsar et al., 1998), amylin + leptin (Roth et al., 2008), CCK + glucagon + bombesin (Hinton et al., 1986), PYY and GLP-1 (Paulik et al., 2011)). Peptide combinations may thus attain transformational efficacy without invoking burdensome toxic risk. This article is part of a Special Issue entitled 'Central Control of Food Intake'.
    Neuropharmacology 03/2012; 63(1):31-45. DOI:10.1016/j.neuropharm.2012.03.019 · 4.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ZUSAMMENFASSUNG Hintergrund: Die therapierefraktäre arterielle Hypertonie wird als nicht leitlini-engerechte Blutdruckeinstellung trotz antihypertensiver Dreifachtherapie in maximaler oder maximal tolerierter Dosis, unter Einbeziehung eines Diureti-kums, definiert. Mit einer Prävalenz von circa 5–15 % bei Patienten mit Blut-hochdruck ist sie in Haus-und Facharztpraxen allgegenwärtig. Methode: Übersichtsarbeit unter Berücksichtigung der aktuellen Leitlinien und nach selektiver Medline-Literaturrecherche. Ergebnisse: Die Behandlung des therapierefraktären Bluthochdrucks beruht auf einem multimodalen Therapievorgehen mit systematischer Identifikation von sekundären Hypertonieursachen und Ausschluss von Pseudoresistenzen. Die Optimierung des Körpergewichts, salzarme Kost, körperliche Aktivität und Alko-holkarenz stellen wichtige nicht-medikamentöse Behandlungsoptionen dar. Hinzu kommt eine individualisierte pharmakologische Kombinationstherapie mit Substanzen unterschiedlicher Wirkmechanismen. In der Pathophysiologie kommt der Aktivierung des Sympathikus eine übergeordnete Bedeutung zu. Durch die neuerdings verfügbare interventionelle renale Denervation der sym-pathischen Nervenfasern kommt es bei etwa 84 % der Behandelten zu einer klinisch relevanten und anhaltenden Blutdruckreduktion (Praxisblutdruck im Mittel –32 mmHg systolisch beziehungsweise –12 mmHg nach 6 Monaten, p < 0,001). Dabei konnte die Intervention bei 201 der 206 (98 %) systematisch in Studien erfassten Patienten ohne Komplikationen durchgeführt werden. Zu den klinisch relevanten Komplikationen gehören unter anderem Pseudoaneu-rysmen der A. femoralis sowie eine Nierenarteriendissektion während der Plat-zierung des Ablationskatheters. Schlussfolgerung: Die therapierefraktäre arterielle Hypertonie fordert ein inter-disziplinäres, multimodales Therapieregime. Bei Patienten mit medikamentös nicht ausreichend einstellbarem Bluthochdruck sollten neue und vielverspre-chende Behandlungsoptionen in Erwägung gezogen werden. ►Zitierweise Mahfoud F, Himmel F, Ukena C, Schunkert H, Böhm M, Weil J: Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int 2011; 108(43): 725–31.
Show more